TW202346324A - 前藥及其用途 - Google Patents
前藥及其用途 Download PDFInfo
- Publication number
- TW202346324A TW202346324A TW112117140A TW112117140A TW202346324A TW 202346324 A TW202346324 A TW 202346324A TW 112117140 A TW112117140 A TW 112117140A TW 112117140 A TW112117140 A TW 112117140A TW 202346324 A TW202346324 A TW 202346324A
- Authority
- TW
- Taiwan
- Prior art keywords
- chemical formula
- compound
- glp
- ethoxy
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22172545.0 | 2022-05-10 | ||
| EP22172545 | 2022-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202346324A true TW202346324A (zh) | 2023-12-01 |
Family
ID=81940650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112117140A TW202346324A (zh) | 2022-05-10 | 2023-05-09 | 前藥及其用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250304645A1 (enExample) |
| EP (1) | EP4522220A1 (enExample) |
| JP (1) | JP2025517672A (enExample) |
| CN (1) | CN119173275A (enExample) |
| AR (1) | AR129270A1 (enExample) |
| TW (1) | TW202346324A (enExample) |
| WO (1) | WO2023217744A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025092778A1 (zh) * | 2023-10-31 | 2025-05-08 | 深圳信立泰药业股份有限公司 | Glp-1化合物及其制备方法与应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| WO2010080605A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Dipeptide linked medicinal agents |
| ES2401965T3 (es) | 2009-02-19 | 2013-04-25 | Novo Nordisk A/S | Modificación de Factor VIII |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー/エス | Glp−1アナログ及び誘導体 |
| US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| EP2588126A4 (en) | 2010-06-24 | 2015-07-08 | Univ Indiana Res & Tech Corp | AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS |
| JP6039569B2 (ja) | 2010-11-09 | 2016-12-07 | ノヴォ ノルディスク アー/エス | 二重アシル化されたglp−1誘導体 |
| US9452225B2 (en) | 2012-03-01 | 2016-09-27 | Novo Nordisk A/S | GLP-1 prodrugs |
| JP2016521253A (ja) | 2013-03-15 | 2016-07-21 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 持続性作用を有するプロドラッグ |
| JP6701208B2 (ja) | 2014-09-24 | 2020-05-27 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 脂質化アミド系インスリンプロドラッグ |
| JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー/エス | Glp−1アゴニスト、n−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩及び滑沢剤を含む固形組成物 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
-
2023
- 2023-05-09 AR ARP230101137A patent/AR129270A1/es unknown
- 2023-05-09 US US18/864,190 patent/US20250304645A1/en active Pending
- 2023-05-09 JP JP2024566410A patent/JP2025517672A/ja active Pending
- 2023-05-09 CN CN202380039160.4A patent/CN119173275A/zh active Pending
- 2023-05-09 TW TW112117140A patent/TW202346324A/zh unknown
- 2023-05-09 EP EP23726891.7A patent/EP4522220A1/en active Pending
- 2023-05-09 WO PCT/EP2023/062208 patent/WO2023217744A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN119173275A (zh) | 2024-12-20 |
| WO2023217744A1 (en) | 2023-11-16 |
| US20250304645A1 (en) | 2025-10-02 |
| AR129270A1 (es) | 2024-08-07 |
| JP2025517672A (ja) | 2025-06-10 |
| EP4522220A1 (en) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI850599B (zh) | 前藥及其用途 | |
| US10604555B2 (en) | GIP derivatives and uses thereof | |
| JP5606314B2 (ja) | A−b−c−d−で誘導体化されたペプチドとその治療用途 | |
| JP4585037B2 (ja) | アシル化glp−1化合物 | |
| JP2007537141A (ja) | 新規なglp−1化合物 | |
| JP2010538049A (ja) | 切断型glp−1誘導体及びその治療的使用 | |
| KR20230042019A (ko) | Glp-1 및 gip 수용체 공동-작용제 | |
| KR102704620B1 (ko) | 프로드러그 및 이의 용도 | |
| CN116490212A (zh) | Glp-1前药及其用途 | |
| TW202346324A (zh) | 前藥及其用途 | |
| CA3195872A1 (en) | Glp-1 prodrugs and uses hereof | |
| US12616739B2 (en) | GLP-1 prodrugs and uses thereof |